Abstract
Ramos-Zavala et al. (1) described in their report the effects of diacerein, an anti-inflammatory drug used in the treatment of rheumatic diseases, on insulin secretion in patients with type 2 diabetes. They showed that diacerein induced a significant decrease in fasting glucose levels, A1C levels, tumor necrosis factor-α levels, and interleukin (IL)-1β serum levels. By using the hyperinsulinemic-euglycemic clamp, they also showed that diacerein is able to improve insulin secretion but does not modify insulin sensitivity. Our laboratory recently investigated the antihyperglycemic effect of diacerein and the mechanisms responsible for …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
